Reference

Chemotherapy for pleural mesothelioma

All Rights Reserved. In this study， 137281-23-3 and 15663-27-1 are also used. Chemotherapy for pleural mesothelioma. Gemba, Kenichi (Dep. Respiratory Med., Okayama Rousai Hospital, Japan). Saishin Igaku, 62(1), 86-92 (Japanese) 2007 Saishin Igakusha. CODEN: SAIGAK. ISSN: 0370-8241. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review on chemotherapeutic approaches for pleural mesothelioma, including combination chemotherapy with cisplatin and pemetrexed. .

Pemetrexed: a novel antifolate agent enters clinical practice

Pemetrexed: a novel antifolate agent enters clinical practice. Kut, Victoria; Patel, Jyoti D.; Argiris, Athanassios (The Feinberg School of Medicine, Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA). Expert Review of Anticancer Therapy, 4(4), 511-522 (English) 2004 Future Drugs Ltd. CODEN: ERATBJ. ISSN: 1473-7140. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Pemetrexed (Alimta Eli Lilly) is a multitargeted antifolate that inhibits at least three enzymes in the nucleic acid synthetic pathways. The US Food and Drug Administration recently approved pemetrexed, in combination with cisplatin, for the first-line treatment of advanced malignant pleural mesothelioma. 59-30-3 and 137281-23-3 which are cas registry numbers are also used here. Moreover, pemetrexed was recently shown to be as efficacious as docetaxel (Taxotere Aventis) in the second-line treatment of non-small cell lung cancer, and its toxicity profile was preferable. The main toxicity seen with pemetrexed is myelosuppression, which is considerably reduced by coadministration of folic acid and vitamin B12. Multiple Phase II clin. trials have demonstrated that pemetrexed has promising single-agent activity in many other solid tumors, including head and neck, breast and colorectal cancers. Combination regimens consisting of pemetrexed and other chemotherapeutics or novel mol.-targeted agents are currently under investigation. Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer. .